{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:51:58Z","timestamp":1792633918553,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C15966\/A24375"],"award-info":[{"award-number":["C15966\/A24375"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C15966\/A24375"],"award-info":[{"award-number":["C15966\/A24375"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C15966\/A24375"],"award-info":[{"award-number":["C15966\/A24375"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C15966\/A24375"],"award-info":[{"award-number":["C15966\/A24375"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C15966\/A24375"],"award-info":[{"award-number":["C15966\/A24375"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C15966\/A24375"],"award-info":[{"award-number":["C15966\/A24375"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C15966\/A24375"],"award-info":[{"award-number":["C15966\/A24375"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute myeloid leukaemia (AML) patients harbouring certain chromosome abnormalities have particularly adverse prognosis. For these patients, targeted therapies have not yet made a significant clinical impact. To understand the molecular landscape of poor prognosis AML we profiled 74 patients from two different centres (in UK and Finland) at the proteomic, phosphoproteomic and drug response phenotypic levels. These data were complemented with transcriptomics analysis for 39 cases. Data integration highlighted a phosphoproteomics signature that define two biologically distinct groups of KMT2A rearranged leukaemia, which we term MLLGA and MLLGB. MLLGA presented increased DOT1L phosphorylation, HOXA gene expression, CDK1 activity and phosphorylation of proteins involved in RNA metabolism, replication and DNA damage when compared to MLLGB and no KMT2A rearranged samples. MLLGA was particularly sensitive to 15 compounds including genotoxic drugs and inhibitors of mitotic kinases and inosine-5-monosphosphate dehydrogenase (IMPDH) relative to other cases. Intermediate-risk KMT2A-MLLT3 cases were mainly represented in a third group closer to MLLGA than to MLLGB. The expression of IMPDH2 and multiple nucleolar proteins was higher in MLLGA and correlated with the response to IMPDH inhibition in KMT2A rearranged leukaemia, suggesting a role of the nucleolar activity in sensitivity to treatment. In summary, our multilayer molecular profiling of AML with poor prognosis and KMT2A-MLLT3 karyotypes identified a phosphoproteomics signature that defines two biologically and phenotypically distinct groups of KMT2A rearranged leukaemia. These data provide a rationale for the potential development of specific therapies for AML patients characterised by the MLLGA phosphoproteomics signature identified in this study.<\/jats:p>","DOI":"10.1038\/s41392-022-01288-1","type":"journal-article","created":{"date-parts":[[2023,2,26]],"date-time":"2023-02-26T20:02:34Z","timestamp":1677441754000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4207-9349","authenticated-orcid":false,"given":"Pedro","family":"Casado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6733-9752","authenticated-orcid":false,"given":"Ana","family":"Rio-Machin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-1693","authenticated-orcid":false,"given":"Juho J.","family":"Miettinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Findlay","family":"Bewicke-Copley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Rouault-Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1782-9275","authenticated-orcid":false,"given":"Szilvia","family":"Krizsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alun","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinothini","family":"Rajeeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farideh","family":"Miraki-Moud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Taussig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"B\u00f6d\u00f6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4324-8706","authenticated-orcid":false,"given":"Caroline","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude","family":"Fitzgibbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3426-2274","authenticated-orcid":false,"given":"Pedro R.","family":"Cutillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"1288_CR1","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","volume":"341","author":"B Lowenberg","year":"1999","unstructured":"Lowenberg, B., Downing, J. R. & Burnett, A. Acute myeloid leukemia. N. Engl. J. Med. 341, 1051\u20131062 (1999).","journal-title":"N. Engl. J. Med."},{"key":"1288_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00376-1","volume":"10","author":"N Daver","year":"2020","unstructured":"Daver, N. et al. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J. 10, 107 (2020).","journal-title":"Blood Cancer J."},{"key":"1288_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447 (2017).","journal-title":"Blood"},{"key":"1288_CR4","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/s41375-018-0068-2","volume":"32","author":"AK Eisfeld","year":"2018","unstructured":"Eisfeld, A. K. et al. Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32, 1338\u20131348 (2018).","journal-title":"Leukemia"},{"key":"1288_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.leukres.2018.01.008","volume":"66","author":"Y Harada","year":"2018","unstructured":"Harada, Y. et al. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. Leuk. Res. 66, 20\u201327 (2018).","journal-title":"Leuk. Res."},{"key":"1288_CR6","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","volume":"34","author":"T Herold","year":"2020","unstructured":"Herold, T. et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia 34, 3161\u20133172 (2020).","journal-title":"Leukemia"},{"key":"1288_CR7","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil, E. et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N. Engl. J. Med. 374, 2209\u20132221 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1288_CR8","doi-asserted-by":"publisher","first-page":"26340","DOI":"10.1073\/pnas.2014732117","volume":"117","author":"M Bill","year":"2020","unstructured":"Bill, M. et al. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23\/KMT2A. Proc. Natl Acad. Sci. 117, 26340\u201326346 (2020).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1288_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fcell.2019.00081","volume":"7","author":"AKN Chan","year":"2019","unstructured":"Chan, A. K. N. & Chen, C. W. Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions. Front Cell Dev. Biol. 7, 81 (2019).","journal-title":"Front Cell Dev. Biol."},{"key":"1288_CR10","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2007-09-113597","volume":"113","author":"J Faber","year":"2009","unstructured":"Faber, J. et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 113, 2375\u20132385 (2009).","journal-title":"Blood"},{"key":"1288_CR11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nrc3929","volume":"15","author":"RC Rao","year":"2015","unstructured":"Rao, R. C. & Dou, Y. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat. Rev. Cancer. 15, 334\u2013346 (2015).","journal-title":"Nat. Rev. Cancer."},{"key":"1288_CR12","doi-asserted-by":"publisher","first-page":"194548","DOI":"10.1016\/j.bbagrm.2020.194548","volume":"1863","author":"S Takahashi","year":"2020","unstructured":"Takahashi, S. & Yokoyama, A. The molecular functions of common and atypical MLL fusion protein complexes. Biochim Biophys. Acta Gene Regul. Mech. 1863, 194548 (2020).","journal-title":"Biochim Biophys. Acta Gene Regul. Mech."},{"key":"1288_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/nrg.2016.10","volume":"17","author":"SA Byron","year":"2016","unstructured":"Byron, S. A., Van Keuren-Jensen, K. R., Engelthaler, D. M., Carpten, J. D. & Craig, D. W. Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat. Rev. Genet. 17, 257\u2013271 (2016).","journal-title":"Nat. Rev. Genet."},{"key":"1288_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354 (2016).","journal-title":"Nature"},{"key":"1288_CR15","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","volume":"20","author":"JC Marine","year":"2020","unstructured":"Marine, J. C., Dawson, S. J. & Dawson, M. A. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer. 20, 743\u2013756 (2020).","journal-title":"Nat. Rev. Cancer."},{"key":"1288_CR16","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1038\/s41375-018-0032-1","volume":"32","author":"P Casado","year":"2018","unstructured":"Casado, P. et al. Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. Leukemia 32, 1818\u20131822 (2018).","journal-title":"Leukemia"},{"key":"1288_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1074\/mcp.M112.017483","volume":"11","author":"MP Alcolea","year":"2012","unstructured":"Alcolea, M. P., Casado, P., Rodriguez-Prados, J. C., Vanhaesebroeck, B. & Cutillas, P. R. Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol. Cell Proteom. 11, 453\u2013466 (2012).","journal-title":"Mol. Cell Proteom."},{"key":"1288_CR18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cell.2020.06.012","volume":"182","author":"YJ Chen","year":"2020","unstructured":"Chen, Y. J. et al. Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression. Cell 182, 226\u2013244 e217 (2020).","journal-title":"Cell"},{"key":"1288_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.cell.2019.08.052","volume":"179","author":"Q Gao","year":"2019","unstructured":"Gao, Q. et al. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. Cell 179, 561\u2013577 e522 (2019).","journal-title":"Cell"},{"key":"1288_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11452-x","volume":"10","author":"PA Stewart","year":"2019","unstructured":"Stewart, P. A. et al. Proteogenomic landscape of squamous cell lung cancer. Nat. Commun. 10, 3578 (2019).","journal-title":"Nat. Commun."},{"key":"1288_CR21","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.cell.2016.05.069","volume":"166","author":"H Zhang","year":"2016","unstructured":"Zhang, H. et al. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. Cell 166, 755\u2013765 (2016).","journal-title":"Cell"},{"key":"1288_CR22","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/bib\/bbx141","volume":"20","author":"G Giudice","year":"2019","unstructured":"Giudice, G. & Petsalaki, E. Proteomics and phosphoproteomics in precision medicine: applications and challenges. Brief. Bioinform. 20, 767\u2013777 (2019).","journal-title":"Brief. Bioinform."},{"key":"1288_CR23","doi-asserted-by":"publisher","first-page":"e1900312","DOI":"10.1002\/pmic.201900312","volume":"21","author":"G Mantini","year":"2021","unstructured":"Mantini, G., Pham, T. V., Piersma, S. R. & Jimenez, C. R. Computational Analysis of Phosphoproteomics Data in Multi-Omics Cancer Studies. Proteomics 21, e1900312 (2021).","journal-title":"Proteomics"},{"key":"1288_CR24","doi-asserted-by":"publisher","first-page":"eabl7989","DOI":"10.1126\/scisignal.abl7989","volume":"15","author":"F Pedicona","year":"2022","unstructured":"Pedicona, F. et al. Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment. Sci. Signal. 15, eabl7989 (2022).","journal-title":"Sci. Signal."},{"key":"1288_CR25","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1182\/blood-2003-02-0434","volume":"102","author":"C Schoch","year":"2003","unstructured":"Schoch, C. et al. AML with 11q23\/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 102, 2395\u20132402 (2003).","journal-title":"Blood"},{"key":"1288_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","volume":"20","author":"KM Bernt","year":"2011","unstructured":"Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 20, 66\u201378 (2011).","journal-title":"Cancer Cell."},{"key":"1288_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc2876","volume":"10","author":"P Chi","year":"2010","unstructured":"Chi, P., Allis, C. D. & Wang, G. G. Covalent histone modifications\u2013miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer. 10, 457\u2013469 (2010).","journal-title":"Nat. Rev. Cancer."},{"key":"1288_CR28","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/S0960-9822(02)00901-6","volume":"12","author":"Q Feng","year":"2002","unstructured":"Feng, Q. et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr. Biol. 12, 1052\u20131058 (2002).","journal-title":"Curr. Biol."},{"key":"1288_CR29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.celrep.2015.04.004","volume":"11","author":"A Kuntimaddi","year":"2015","unstructured":"Kuntimaddi, A. et al. Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential. Cell Rep. 11, 808\u2013820 (2015).","journal-title":"Cell Rep."},{"key":"1288_CR30","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/leu.2010.316","volume":"25","author":"M Pigazzi","year":"2011","unstructured":"Pigazzi, M. et al. MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study. Leukemia 25, 560\u2013563 (2011).","journal-title":"Leukemia"},{"key":"1288_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nm.4439","volume":"24","author":"H Bolouri","year":"2018","unstructured":"Bolouri, H. et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat. Med. 24, 103\u2013112 (2018).","journal-title":"Nat. Med."},{"key":"1288_CR32","doi-asserted-by":"publisher","first-page":"rs6","DOI":"10.1126\/scisignal.2003573","volume":"6","author":"P Casado","year":"2013","unstructured":"Casado, P. et al. Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells. Sci. Signal 6, rs6 (2013).","journal-title":"Sci. Signal"},{"key":"1288_CR33","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3389\/fonc.2015.00278","volume":"5","author":"V Bavetsias","year":"2015","unstructured":"Bavetsias, V. & Linardopoulos, S. Aurora Kinase Inhibitors: Current Status and Outlook. Front Oncol. 5, 278 (2015).","journal-title":"Front Oncol."},{"key":"1288_CR34","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1158\/0008-5472.CAN-18-3631","volume":"79","author":"T Ubhi","year":"2019","unstructured":"Ubhi, T. & Brown, G. W. Exploiting DNA Replication Stress for Cancer Treatment. Cancer Res. 79, 1730\u20131739 (2019).","journal-title":"Cancer Res."},{"key":"1288_CR35","doi-asserted-by":"publisher","unstructured":"Naffouje, R. et al. Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story. Cancers (Basel) 11, https:\/\/doi.org\/10.3390\/cancers11091346 (2019).","DOI":"10.3390\/cancers11091346"},{"key":"1288_CR36","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.molmet.2020.02.005","volume":"35","author":"A Siddiqui","year":"2020","unstructured":"Siddiqui, A. & Ceppi, P. A non-proliferative role of pyrimidine metabolism in cancer. Mol. Metab. 35, 100962 (2020).","journal-title":"Mol. Metab."},{"key":"1288_CR37","doi-asserted-by":"publisher","first-page":"9449","DOI":"10.1093\/nar\/gkaa713","volume":"48","author":"LM Korsholm","year":"2020","unstructured":"Korsholm, L. M. et al. Recent advances in the nucleolar responses to DNA double-strand breaks. Nucl. Acids Res. 48, 9449\u20139461 (2020).","journal-title":"Nucl. Acids Res."},{"key":"1288_CR38","doi-asserted-by":"publisher","first-page":"6811","DOI":"10.1093\/nar\/gkz436","volume":"47","author":"AK Velichko","year":"2019","unstructured":"Velichko, A. K. et al. Hypoosmotic stress induces R loop formation in nucleoli and ATR\/ATM-dependent silencing of nucleolar transcription. Nucl. Acids Res. 47, 6811\u20136825 (2019).","journal-title":"Nucl. Acids Res."},{"key":"1288_CR39","doi-asserted-by":"publisher","first-page":"6096","DOI":"10.1073\/pnas.96.11.6096","volume":"96","author":"J Klein","year":"1999","unstructured":"Klein, J. & Grummt, I. Cell cycle-dependent regulation of RNA polymerase I transcription: the nucleolar transcription factor UBF is inactive in mitosis and early G1. Proc. Natl Acad. Sci. 96, 6096\u20136101 (1999).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1288_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12929-020-00674-7","volume":"27","author":"HA Hou","year":"2020","unstructured":"Hou, H. A. & Tien, H. F. Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies. J. Biomed. Sci. 27, 81 (2020).","journal-title":"J. Biomed. Sci."},{"key":"1288_CR41","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.5045\/br.2020.S003","volume":"55","author":"S Park","year":"2020","unstructured":"Park, S., Cho, B. S. & Kim, H. J. New agents in acute myeloid leukemia (AML).Blood Res. 55, S14\u2013S18 (2020).","journal-title":"Blood Res."},{"key":"1288_CR42","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade, D. et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116, 354\u2013365 (2010).","journal-title":"Blood"},{"key":"1288_CR43","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.cell.2019.03.030","volume":"177","author":"S Vasaikar","year":"2019","unstructured":"Vasaikar, S. et al. Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities. Cell 177, 1035\u20131049 e1019 (2019).","journal-title":"Cell"},{"key":"1288_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/srep05193","volume":"4","author":"B Yadav","year":"2014","unstructured":"Yadav, B. et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci. Rep. 4, 5193 (2014).","journal-title":"Sci. Rep."},{"key":"1288_CR45","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1600-0609.2009.01305.x","volume":"83","author":"L Trentin","year":"2009","unstructured":"Trentin, L. et al. Two independent gene signatures in pediatric t(4;11) acute lymphoblastic leukemia patients. Eur. J. Haematol. 83, 406\u2013419 (2009).","journal-title":"Eur. J. Haematol."},{"key":"1288_CR46","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1182\/blood-2009-07-233049","volume":"115","author":"RW Stam","year":"2010","unstructured":"Stam, R. W. et al. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood 115, 2835\u20132844 (2010).","journal-title":"Blood"},{"key":"1288_CR47","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1182\/blood-2011-10-382861","volume":"119","author":"H Kang","year":"2012","unstructured":"Kang, H. et al. Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children\u2019s Oncology Group study. Blood 119, 1872\u20131881 (2012).","journal-title":"Blood"},{"key":"1288_CR48","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccell.2016.10.008","volume":"30","author":"S Lin","year":"2016","unstructured":"Lin, S. et al. Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia. Cancer Cell. 30, 737\u2013749 (2016).","journal-title":"Cancer Cell."},{"key":"1288_CR49","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/bloodadvances.2020001922","volume":"4","author":"MC Kingsley","year":"2020","unstructured":"Kingsley, M. C. et al. Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML. Blood Adv. 4, 3109\u20133122 (2020).","journal-title":"Blood Adv."},{"key":"1288_CR50","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1091\/mbc.e06-03-0241","volume":"17","author":"T Tsuji","year":"2006","unstructured":"Tsuji, T., Ficarro, S. B. & Jiang, W. Essential role of phosphorylation of MCM2 by Cdc7\/Dbf4 in the initiation of DNA replication in mammalian cells. Mol. Biol. Cell. 17, 4459\u20134472 (2006).","journal-title":"Mol. Biol. Cell."},{"key":"1288_CR51","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/nrm2831","volume":"11","author":"MS Huen","year":"2010","unstructured":"Huen, M. S., Sy, S. M. & Chen, J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat. Rev. Mol. Cell Biol. 11, 138\u2013148 (2010).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1288_CR52","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3324\/haematol.2018.214882","volume":"105","author":"H Kuusanmaki","year":"2020","unstructured":"Kuusanmaki, H. et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica 105, 708\u2013720 (2020).","journal-title":"Haematologica"},{"key":"1288_CR53","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","volume":"114","author":"BV Balgobind","year":"2009","unstructured":"Balgobind, B. V. et al. Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 114, 2489\u20132496 (2009).","journal-title":"Blood"},{"key":"1288_CR54","doi-asserted-by":"publisher","unstructured":"Guest, E. M. et al. Prognostic Significance of 11q23\/MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children\u2019s Oncology Group (COG) Trial AAML0531. Blood 128, https:\/\/doi.org\/10.1182\/blood.V128.22.1211.1211 (2016).","DOI":"10.1182\/blood.V128.22.1211.1211"},{"key":"1288_CR55","doi-asserted-by":"publisher","first-page":"194564","DOI":"10.1016\/j.bbagrm.2020.194564","volume":"1863","author":"S Rice","year":"2020","unstructured":"Rice, S. & Roy, A. MLL-rearranged infant leukaemia: A \u2018thorn in the side\u2019 of a remarkable success story. Biochim Biophys. Acta Gene Regul. Mech. 1863, 194564 (2020).","journal-title":"Biochim Biophys. Acta Gene Regul. Mech."},{"key":"1288_CR56","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fped.2017.00004","volume":"5","author":"AC Winters","year":"2017","unstructured":"Winters, A. C. & Bernt, K. M. MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Front Pediatr. 5, 4 (2017).","journal-title":"Front Pediatr."},{"key":"1288_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00557-6","volume":"11","author":"GC Issa","year":"2021","unstructured":"Issa, G. C. et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 11, 162 (2021).","journal-title":"Blood Cancer J."},{"key":"1288_CR58","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbmt.2005.06.004","volume":"12","author":"W Blum","year":"2006","unstructured":"Blum, W. et al. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. Biol. Blood Marrow Transpl. 12, 61\u201367 (2006).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1288_CR59","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/bjh.16432","volume":"189","author":"E Onecha","year":"2020","unstructured":"Onecha, E. et al. Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity. Br. J. Haematol. 189, 672\u2013683 (2020).","journal-title":"Br. J. Haematol."},{"key":"1288_CR60","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","volume":"3","author":"T Pemovska","year":"2013","unstructured":"Pemovska, T. et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Disco. 3, 1416\u20131429 (2013).","journal-title":"Cancer Disco."},{"key":"1288_CR61","doi-asserted-by":"publisher","unstructured":"Goyama, S. et al. Inhibition of Impdh As an Effective Treatment for MLL-Fusion Leukemia. Blood 128, https:\/\/doi.org\/10.1182\/blood.V128.22.750.750 (2016).","DOI":"10.1182\/blood.V128.22.750.750"},{"key":"1288_CR62","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/ijc.1464","volume":"94","author":"BJ Barnes","year":"2001","unstructured":"Barnes, B. J., Izydore, R. A., Eakin, A. E. & Hall, I. H. Mechanism of action of the antitumor agents 6-benzoyl-3,3-disubstituted-1,5-diazabicyclo[3.1.0]hexane-2,4-diones: potent inhibitors of human type II inosine 5\u2019-monophosphate dehydrogenase. Int J. Cancer. 94, 275\u2013281 (2001).","journal-title":"Int J. Cancer."},{"key":"1288_CR63","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/s41556-019-0363-9","volume":"21","author":"S Kofuji","year":"2019","unstructured":"Kofuji, S. et al. IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma. Nat. Cell Biol. 21, 1003\u20131014 (2019).","journal-title":"Nat. Cell Biol."},{"key":"1288_CR64","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cmet.2018.06.005","volume":"28","author":"F Huang","year":"2018","unstructured":"Huang, F. et al. Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. Cell Metab. 28, 369\u2013382 e365 (2018).","journal-title":"Cell Metab."},{"key":"1288_CR65","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/jb\/mvaa085","volume":"168","author":"S Kofuji","year":"2020","unstructured":"Kofuji, S. & Sasaki, A. T. GTP metabolic reprogramming by IMPDH2: unlocking cancer cells\u2019 fuelling mechanism. J. Biochem. 168, 319\u2013328 (2020).","journal-title":"J. Biochem."},{"key":"1288_CR66","doi-asserted-by":"publisher","unstructured":"Felipe-Abrio, B. & Carnero, A. The Tumor Suppressor Roles of MYBBP1A, a Major Contributor to Metabolism Plasticity and Stemness. Cancers (Basel) 12, https:\/\/doi.org\/10.3390\/cancers12010254 (2020).","DOI":"10.3390\/cancers12010254"},{"key":"1288_CR67","doi-asserted-by":"publisher","unstructured":"Ferreira, R., Schneekloth, J. S., Jr, Panov, K. I., Hannan, K. M. & Hannan, R. D. Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age. Cells 9, https:\/\/doi.org\/10.3390\/cells9020266 (2020).","DOI":"10.3390\/cells9020266"},{"key":"1288_CR68","doi-asserted-by":"publisher","first-page":"16217","DOI":"10.18632\/oncotarget.7479","volume":"7","author":"X He","year":"2016","unstructured":"He, X., Li, Y., Dai, M. S. & Sun, X. X. Ribosomal protein L4 is a novel regulator of the MDM2-p53 loop. Oncotarget 7, 16217\u201316226 (2016).","journal-title":"Oncotarget"},{"key":"1288_CR69","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/nar\/gkq1050","volume":"39","author":"M Wang","year":"2011","unstructured":"Wang, M. & Pestov, D. G. 5\u2019-end surveillance by Xrn2 acts as a shared mechanism for mammalian pre-rRNA maturation and decay. Nucl. Acids Res. 39, 1811\u20131822 (2011).","journal-title":"Nucl. Acids Res."},{"key":"1288_CR70","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1093\/bioinformatics\/btaa138","volume":"36","author":"S Potdar","year":"2020","unstructured":"Potdar, S. et al. Breeze: an integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics 36, 3602\u20133604 (2020).","journal-title":"Bioinformatics"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01288-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01288-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01288-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,26]],"date-time":"2023-02-26T20:02:42Z","timestamp":1677441762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01288-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1288"],"URL":"https:\/\/doi.org\/10.1038\/s41392-022-01288-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.11.10.515949","asserted-by":"object"}]},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]},"assertion":[{"value":"20 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.R.C. is cofounder and director of Kinomica Ltd. C.H. has received funding from BMS\/Celgene, Kronos Bio, Novartis, Oncopeptides, Orion Pharma, and the IMI2 projects HARMONY and HARMONY PLUS. All other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}